The influence of glutamic acid (E)-alanine (A) dimorphism at position 74 of the DR4(3 chain on cytotoxic T cell recognition of an antigenic rubella virus peptide, E1 (273-284), was studied using a panel of B cell lines and B cell transfectants expressing different HLA-DRB1 alleles as antigenpresenting cells and targets in 51 Cr-release assays. Only B cell lines expressing the DRB1*0403, DRB1*0406 or DRB 1*0407 subtypes which shared a residue, E, at position 74 in the DR4p chain when sensitized with E1 (273-284) elicited strong cytotoxic T lymphocyte responses. However, in direct binding and antibody inhibition assays, it was shown that biotinylated E1 (272-285) could bind to DR molecules with residues other than E at position 74, including DRB1*0401, DRB1*0404 and DRBT1101 expressed on transfectants. E1 (272-285) bound with similar affinity to the transfectant with DRBT0403, which has E at position 74, as well as the transfectant with DRB1*0404, which does not. When T-B cell engagement rates were compared in cell conjugate assays, the percentage of T-B conjugates was higher when peptide-pulsed transfectants with DRB1*0403 were used than with transfectants expressing DRB1*0404. Hence, the HLA DRp*1 polymorphism at position 74, while not critical for the binding affinity of E1 (272-285) to the HLA molecule, appears to be a primary determinant of restricted recognition and subsequent activation of the peptide-specific T cells.
Introduction
Molecules encoded within the class II region of the MHC are polymorphic, non-covalently associated cx| 3 heterodimers expressed at the surface of specialized antigen-presenting cells. These molecules function as genetic restriction elements in the recognition of foreign antigen by CD4 + T cells (1) . The three-dimensional structure of the class II histocompatibility glycoprotein (HLA-DR1) from human B cell membranes determined by X-ray crystallography is consistent with this function. Peptides are bound in an extended conformation that projects from both ends of an 'open-ended' antigen-binding groove. The N-terminal domains of both the a and (J chains form a helices which border anti-parallel p sheets lining the floor of the peptide-binding groove. Within the peptide-binding groove of HLA-DR1 there are several small 'pockets'. Five of these (pockets 1, 4, 6, 7 and 9) accommodate anchor side chains of the bound peptide at positions 1, 4, 6, 7 and 9 respectively (2). Ammo acid polymorphisms in these regions may influence immune responsiveness by affecting either the ability of the MHC molecule to bind antigenic peptide or the ability of the TCR to recognize the complex of MHC and peptide (2) .
Differences among HLA-DR molecules hae been defined within three regions of hypervariability (HVR) found between amino acids 9-13, 25-33 and 57-79, and two regions of more limited variability located between residues 37-48 and 81-86 (3) . Polymorphisms within HLA-DR4 have been identified in at least 19 allehc variants (designated DRB 1*0401-0419) (4) . The sequences of variants DRB1*0401-0408 are shown in Table 1 . Among these DR4 subtypes, two notable substitutions are found at position 74 [alanine (A) for glutamate (E)] and at position 86 [glycine (G) for valine (V)] of the p chains (Table 1 ) (4) . It has been demonstrated (5) that DRip chain substitutions at positions 85 and 86 within pocket '1' of the peptide-binding groove affect the binding and subsequent T cell recognition of an antigenic influenza hemagglutinin peptide. The residues of pocket '4' which are located at the centre of the DR-binding groove play a major and disproportionate influence on T cell recognition of the antigenic peptides in comparison with polymorphisms at other positions in the DRp chain (6) . Recently, Jorgensen et al. suggested a model of the TCR-peptide-MHC complex in which the CDR3 loops provided the primary contact with the peptide lying in the MHC groove, while the flanking CDR1 and 2 loops contacted the cc-hehces of MHC which lay next to the groove (7) . MHC molecule polymorphisms which can modify T cell responses without direct physical participation in the receptor recognition event have also been reported (7) Peptide binding to HLA molecules may be highly specific for a given HLA subtype, or promiscuous, in that a single peptide may interact with diverse HLA molecules (8, 9) . We have previously demonstrated that certain antigenic peptides of rubella virus (RV) proteins could be presented to cloned T cell lines in the context of both HLA-DR4 and HLA-DR 1 (10) , whereas other RV T cell epitopes showed considerably more restricted presentation by only a limited number of DR4 subtypes (11) . The latter study identified two cytotoxic T lymphocyte (CTL) clones originating from a single donor: ATRVC2 (derived from a T cell line stimulated by UV-inactivated RV) and AT177C5 (derived from a T cell line stimulated with synthetic peptide E1 [273] [274] [275] [276] [277] [278] [279] [280] [281] [282] [283] [284] [285] [286] [287] [288] [289] [290] [291] ). Both recognized an antigenic site mapping to residues (273-284) of RV E1 envelope protein. This site has previously been shown to contain a domain which binds murine antibodies with RV-neutralizing activity. T cell recognition of this epitope was shown to be HLA-DR4 subtype restricted (11) . Hence, the results of this study suggested that polymorphisms at position 74 of the DRp chain may critically influence T cell recognition of the antigenic peptide. To further analyze this, the studies reported herein investigated the impact of amino acid substitutions at position 74 of DR4(J chains on the binding of the RV antigenic peptide, E1 (272-285), to DR molecules and its subsequent recognition by the peptide-specific T-cell clone, AT177C5.
Methods

Synthetic peptides
Overlapping peptides (11-19 amino acids) encompassing residues 272-291 (GEVWVTPVIGSQARKCGLHI)of E1 protein of RV strain M33 (11) were synthesized by automated solidphase methods and purified to 95% homogeneity in reversephase HPLC by BioChem Immunosystems (Laval, Quebec).
RV-specific T cell clones
The T cell clone, AT177C5, used for this study was isolated from a CD4 + /CD8" T cell line derived from a single RV seropositive donor with HLA-DR4/DR7 phenotype as described previously (11) (12) (13) . T cell clone was maintained in culture by stimulating at weekly intervals 2X10 5 T cells with peptide E 1(273-291) at a concentration 15 ng/ml in the presence of 1X10 6 autologous, y-irradiated peripheral blood mononuclear cells. Cultures were replenished every 3-5 days with complete RPMI 1640 medium containing 2 mM L-glutamine, 25 mM HEPES, 50 ILJ/ml penicillin, 50 ng/ml streptomycin, 5X10" 5 M 2-mercaptoethanol and 10% FCS, which was also supplemented with 50 U/ml human recombinant IL-2 (Gibco/BRL, Gaithersburg, MD).
(EBV)-transformed B cell lines (EBV-BLs)
Two kinds of EBV-BLs were used as targets in 51 Cr-release assays The EBV-BLs AT (autologous to T cell clone AT177C5), Jula and P9B were established in our laboratories from HLA heterologous donors (DR4/DR7, DR4/DR5 and DR4/ DR2 respectively) as described previously (10, 11) The HLA homozygous EBV-BLs (HCLs) MAT, BSM, YAR, SST, PF, MT, KT3, KT2 and JHa have different HLA-DR phenotypes or DR4 subtypes. The DR p chain sequences of these cell lines are shown in Table 1 .
Transfectant cell lines
Bare lymphocyte syndrome cell line 1 (BLS-1), an EBVtransformed cell line derived from a congenital bare lymphocyte syndrome patient, was transfected by retrovirus-mediated transfers which contain cDNA from HLA-DRA or DRB1 genes (14, 15) . HLA-DR A*0101 or/and B1*0301, B 1*0401, B1*0403, B1*0404, B1*1101 were introduced respectively into BLS-1 cells. The BLS-1 transfectants included BLS-1.a, BLS-1.ocDR3|3, BLS-1. aDR4Dw4p, BLS-1 aDR4Dw13P, BLS-1.aDR4Dw14P and BLS-1.aDR5p. The HCL, MAT, was also similarly transferred with DRB1*0403 (MATDR4Dw13P) or DRB1*0404(MATDR4Dw14P). Expression of transfected HLA-DR molecules in the BLS-1 cells was verified in each case by immunocytofluorometry (15) . Serologic and T cell defined specificities of the transfected cell lines are shown in Table 2 .
Cell-mediated cytotoxicity assay
A standard 51 Cr-release assay was used to measure CTL responses (10, 11, 16) . For use as CTL targets, EBV-BLs or transfectant cells (1X10 6 ) were sensitized by incubating at 37°C for 1 h with different concentrations of peptide in complete RPMI medium. Unless otherwise indicated, the peptides were used at a final concentration of 10 u.M. After sensitization with peptides, 1X10 6 cells were washed once with complete medium and internally labeled for 1 h at 37°C with 100 nCi of Na 2 51 CrO 4 (Amersham, Ontario, Canada). Radiolabeled target cells were washed four times with medium, then incubated for 4 h at 37°C with T cells at different effector/target ratios in round-bottomed 96-well plates (Nunc, Denmark). All assays were performed in triplicate. Percent 
The amino acid sequences of the first domain of DRp chains of EBV-BLs used in this study are shown The standard one-letter amino acid code is used. A dash indicates identity to the DRBT0401 sequence. AT, Jula and P9B are EBV-BLs with heterozygous HLA-DR phenotypes (DR4/DR7, DR4/DR5 and DR4/DR2 respectively). SST cells share the same HLA DR4 subtype with the cell line AT which is the autologous to the T cell clone AT177C5. 
Peptide-binding assays
The E1 (272-285) peptide (GEVWVTPVIGSQAR) was biotinylated by a modification of previously reported techniques (17) (18) (19) . Briefly, the peptide and a threefold molar excess of /v-hydroxysuccinimide-conjugated biotin (NHS-AC-biotin; Sigma) were dissolved in 0.1 M sodium bicarbonate (pH 9.8) and incubated for 3 h at room temperature. Uncoupled biotin was separated from the biotinylated peptide by dialysis against PBS (0.01 M NaH 2 PO 4 and 0.15 M NaCI, pH 7.2).
For peptide binding assays, SST cells, an HCL which expresses the same DR4 subtype as EBV-BL (AT) cells (autologous to the T cell clone, AT177C5) or BLS-1 transfectants were suspended at a concentration of 1.5 x10 6 cells/ml in RPMI 1640 medium supplemented with 5% FCS and cultured at 37°C, 5% CO 2 To further compare the abilities of different DR molecules to bind to particular peptides, another peptide-binding assay (20, 21) was employed. Briefly, 1.5X10
6 DR-transfected BLS-1 cells were washed twice in HBSS and fixed by incubating with 0 5% paraformaldehyde for 10 min. Cells were washed twice in Iscove's medium supplemented with 10% FCS and then once in PBS. Cells were then resuspended with various concentrations of biotinylated peptide in 150 mM citratephosphate buffer, pH 5 4, 1 mM phenylmethylsulfonyl fluoride (PMSF) in a 200 nl reaction volume for 24 h at 37°C. Cells were washed twice in HBSS before lysis in a buffer containing 0 5% NP 40, 0.15 M NaCI, 50 mM Tris, pH 8 0 and protease inhibitors (PMSF, leupeptin and pepstatin) The lysates were cleared by centrifugation, then transferred to 96-well plates pre-coated with 10 ng/ml mAb L243 (22) and blocked with 5% FCS in PBS. The reaction mixture was neutralized with an equal volume of 50 mM Tris, pH 8 0, containing 0.75% octylglucopyranoside and incubated overnight at 4°C. The wells were then washed with PBS containing 0.02% Tween 20 Europium-labeled streptavidin (Wallac, MA) was added in the presence of 200 \i\ DELFIA assay buffer (Wallac) and incubated at 4 C C for 4 h The wells were washed again Enhancement buffer (Wallac) was then added and the resultant fluorescence was measured using a DELFIA 1232 fluorometer.
mAb
Munne anti-human HLA class I and II mAb were used to inhibit binding of B-E1 (272-285) to EBV-BLs. These were: mAb W6/32 (anti-HLA-A, -B and -C) (23), mAb L243 (anti-HLA-DR) (22) and mAb IVD12 (anti-HLA-DQ) (24) All mAb were obtained from cell culture supernatants of hybridoma cells purchased from the ATCC (Rockville, MD). mAb were used at a final dilution of 1:5 to inhibit peptide binding by incubating SST or BLS-1 transfectant cells with mAb for 30 min before adding biotinylated peptide
Cell conjugate formation and immunofluorescence labeling
A modification of the cell conjugate assays described by Kupfer and Ruppert et al. (25, 26) ) was used to test the ability of peptide-sensitized B cells to engage T cells bearing the appropriate receptor. BLS-1.aDR4Dw13p or BLS-1.ccDR4Dw14p cells (1X10 6 ml in RPMI 1640 medium with 2% FCS) were incubated for 1 h at 37°C with various concentrations of E1 (272-285), then washed to remove unbound peptide. As a control, the BLS-1 transfectant cells were incubated with medium alone. Peptide-pulsed and control cells were fixed with freshly prepared 1% paraformaldehyde for 20 min, then washed in PBS with 2% BSA. The fixed B cells (5X10 4 well) and cloned T cells (AT177C5) were coincubated at a 1:1 ratio in complete RPMI 1640 medium at a total volume of 0.2 ml/well in 96-well round-bottom plates. After 1 h, the incubated cells were pipetted vigorously, then washed in PBS with 2% BSA. The mixed cells were resuspended in PBS with 2% BSA and labeled with FITCmouse anti-CD20 (mAb H2 99) and PE-mouse anti-CD4 (mAb SFC112T4D11) (Coulter Immunology, Ontario, Canada) at final concentration of 5 ng/ml on ice for 30 min After the cells were washed, the T-B conjugates were enumerated by flow cytometry. The percentage of double-stained (engaged) cells represented the frequency of T-B cell conjugates.
Results
Influence of ammo acid polymorphism at residue position 74 of the HLA-DR4J5 chain on cloned CTL recognition of the RV E1 peptide
We demonstrated earlier (11) that the T cell clone, AT177C5, was specific for the RV E1 (273-284) peptide and was restricted by a limited set of DR4 subtypes (11) . In this study, we further examined the restrictive elements by using larger panel of EBV-BLs expressing different HLA-DR4 subtypes. These EBV-BLs were sensitized with E1(273-284) or E 1(272-282) and used as targets in cytotoxicity assays Only EBV-BL which have glutamic acid (E) at position 74 of the DR4(3 chain could present these antigenic peptides to the CTL clone AT177C5 ( Table 3 ), suggesting that DR4p chain residue 74-E was important for T cell recognition
To confirm this, we used a panel of transfectant cell lines derived from the BLS-1 and MAT cell lines (14,15) (shown in Table 2 ). BLS-1 is an EBV-BL derived from the peripheral blood of a bare lymphocyte syndrome patient whose B cells failed to express HLA-DR, -DQ and -DP molecules due to a regulatory defect in HLA class II gene expression (27) Using BLS-1 and MAT transfectants expressing DR4Dw13p (DRB1*0403) or DR4Dw14p (DRB1*0404) phenotypes which differed only at position 74 (residue E to A) in the DR4P chain, as targets in cytotoxicity assays performed with AT177C5 CTL, it was observed that only DR4Dw13P(DRB1*0403) transfectants (phenotype: 74-E) sensitized with E1 (273-284) were able to elicit strong CTL responses of clone, AT177C5 (Figs  1 and 2) .
Characterization of the binding of antigenic peptide E1(272-285) to HLA DR
The DR4P chain amino acid at position 74 is predicted to lie on the solvent-exposed surface of the p chain a helix with its side chain pointing inwards relative to the peptide-binding groove (1,2) As such, position 74 may potentially influence peptide interactions with the HLA-binding groove and the TCR. To examine the influence of 74-E on recognition of the epitope represented in E1 (273-284) by the CTL clone AT177C5, we used the biotinylated E1 (272-285) in direct binding assays. The longer sequence was chosen because we showed earlier (11) that the N-terminal glutamic acid (E) of peptide E1(273-284) was important for T cell recognition. Hence, to avoid disrupting the antigenicity of E1 (273-284) by biotmylation, the longer peptide, E1 (272-285), was modified for the HLA-binding study. Biotinylation was carried out at pH of 9.8 to ensure biotinylation of primary amino groups (pK a = 9.78) rather than ternary amines such as the arginine (R) (pK a = 12.48) located at positon E1 285. To ensure that biotinylation had not disrupted functional antigenicity, both biotinylated and unbiotinylated forms of the peptides, 
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Effector/Target Ratio B-E1 (272-285) and E1 (272-285), were tested in cytotoxicity assays as described above. AT177C5 CTL were equally cytotoxic for both biotinylated and unbiotinylated peptides presented on SST cells, confirming biotinylation did not influence the T cell recognition (Fig. 3) . To identify which HLA molecule was involved in binding to B-E1 (272-285), SST cells were co-incubated with B-E1 (272-285) and mAb. Anti-DR mAb L234 reduced the fluorescent signal substantially, while the anti-DQ and anti-HLA class I mAbs did not (Fig 4) 
Interaction of the peptide E 1(272-285) with heterologous HLA-DR molecules
The interaction of E1 (272-285) with different HLA-DR molecules was examined by direct binding experiments in which B-E1 (272-285) was incubated with viable BLS-1 transfectants expressing various DR types or DR4 subtypes. B-E1(272-285) bound in a dose-dependent manner to the following BLS-1 transfectants: BLS-1.aDR4Dw13P(DRB1*0403), BLS-1 .aDR4Dw14p(DRB 1 *0404), BLS-1 .aDR4Dw4(3(DRB 1 *0401) Effector/Target Ratio and BLS-1.aDR5|3(DRB1*1101) In all cases, binding of B-E1 (272-285) was inhibited by anti-HLA-DR mAb, suggesting DR-specific peptide interaction (data not shown). Kinetic studies revealed that B-E1 (272-285) binding to SST cells and BLS-1 transfectants was detectable after 30 mm, continued to increase with time and was maximal at 16-24 h (Fig. 5) . To determine if amino acid substitutions at position 74 of the HLA-DR4(3 chain influenced peptide affinity for HLA, the kinetics of B-E1 (272-285) binding to BLS-1 transfectants was examined. The results showed that after extending the incubation time to 24 h, B-E 1(272-285) bound similarly to both BLS-1. aDR4Dw13P(DRB1*0403) and BLS-1. ctDR4Dw14P(DRB1*0404) (Fig. 5) . The percent specific cytotoxicity with E1(272-285)-sensitized BLS-1.ocDR4Dw13P(DRB 1*0403) cells as targets, however, was much higher than that observed with BLS-1.ccDR4Dw14p (DRB1 *0404) targets sensitized with the same peptide (Fig. 6) .
To further examine the avidity of binding between peptide E1 (272-285) and the HLA-DR variants, a DR-peptide binding and isolation assay was also used. Results established that biotinylated peptide E1(272-285) could bind to both DRocDR4Dw13P and DRaDR4Dw14p molecules with similar binding intensity (Fig. 7) . We found that the E1 (272-285) peptide efficiently binds to molecules encoded by DRBT0401, *0403, *0404 and *1101; however, no B-E1(272-285) binding was detected to the DRB1 *0301 allele expressed in transfected BLS-1.aDR3P in a similar assay (28) .
The interactions of peptide E1(272-285)-pulsed BLS-1. ccDR4Dw13{l and BLS-1. aDR4Dw 140 B cell lines with cloned AT177C5 T cells
To directly examine the effects of DR4P chain position 74 amino acid substitutions on T cell recognition of B cells presenting E1(272-285), we used a modified cell conjugate assay (25, 26) to determine the frequency of peptide-specific T-B cell engagement As the CTL clone AT177C5 was earlier determined to be CD4+CD8" (11) , T cells bound to peptide E1(272-285)-pulsed B cells were identified using a PE-anti-CD4 mAb. FITC-anti-CD20 mAb was used to identify B cells. Thus, we were able to establish the percentages of the engaged (T-B conjugates) lymphocytes by dual-color flow cytometry. The T-B cell conjugate frequency of peptidepulsed BLS-1.aDR4Dw13P(DRB1*0403) cells (20.8%) was higher than that observed with peptide-pulsed BLS-1.aDR4Dw14P(DRB 1*0404) cells (5.7%). Non-specific frequency of conjugate formation of the B cells and T cells in the absence of peptide E 1(272-285) was in the range of 3-5% in all experiments (Fig. 8) . The conjugation frequency of BLS-1 .o£>R4Dw13p and T cells increased in a direct dosedependent manner with peptide E 1(272-285) concentration. Moreover, the dose-response curve observed for T-B conjugate formation paralleled that observed in cytotoxicity assays employing BLS-1.aDR4Dw13P cells pulsed with E1(272-285) as targets (Fig. 9) .
Discussion
Live, attenuated RV vaccines have been used effectively to immunize infants and susceptible women of child-bearing age for two decades (29) . However, concerns about primary or secondary vaccine failure and the relatively high incidence (10-15%) of RV vaccine-associated arthritis in adult female vaccinees are an impetus for the development of an improved second generation vaccine employing only antigenic regions known to give rise to protective immunity (30) (31) (32) . To identify protective epitopes on RV proteins which might be suitable candidates for a synthetic peptide-based vaccine, we had previously characterized antigenic sites that were recognized primarily by cloned CD4 + cytotoxic T cells (10) (11) (12) (13) 16) . These investigations revealed some RV E1-specific clones (such as AT177C5 used in the present study) appeared to be DR4 subtype restricted (11) , suggesting that amino acid polymorphisms within variable subregions of the DR4 molecule such as position 74 in pocket '4' might influence either peptide binding or TCR recognition. For this reason the present study examined the influence of glutamic acid (E) at position 74 of the HLA-DR4P chain on the presentation and recognition, by AT177C5 cloned CTL, of the epitope represented in the synthetic peptide, E 1(273-284).
HLA class ll-restricted, antigen-specific T cell recognition requires the TCR to recognize a unique three-dimensional conformation of a complex formed by an antigenic peptide bound to the HLA class II molecule. Amino acid polymorphisms among HLA class II molecules play an important role in the specificity of these interactions and are the basis for class ll-restricted T cell recognition. Some of these polymorphisms are thought to determine which peptides may bind to a particular class II molecule, whereas others are thought to be more involved with TCR recognition of the peptide HLA complex (5, 33) . A single amino acid substitution in a DR(3 chain might influence T cell recognition of an antigenic peptide through three possible mechanisms: (i) by preventing binding of the peptide to the DR molecule, (ii) by inducing a conformational change that alters the contacts between the peptide and TCR or (iii) by causing the loss of a critical contact between the class II molecule and the TCR (7) . Comparison of the amino acid sequences of the first domains of the DR4p Table 1 suggests that polymorphisms at residues 57, 67, 70, 71, 74 and 86, which distinguish the DR4 subtypes, may influence presentation of the E1 peptides as shown in Table 3 . The residue at DRp chain position 74, located at the center of the DR-binding groove and at the end of pocket '4', exhibits the highest degree of polymorphism. Amino acids found at this position in the various DR allelic variants include residues with different size, charge and polarity: A, L, E, Q or R (4).
O'Sullivan et al have described a nine residue peptide-HLA-DR interacting motif composed of an aromatic or hydrophobic amino acid in position 1, followed by a non-charged and relatively small residue in position 6, and another relatively hydrophobic one in position 9 (34, 35) . A recent study of DRB1 allelic specificity in peptide binding showed that seven to eight peptide core sequences which bound to HLA-DR4 had the residues F, L or V at position 1 and N, Q, S or T at position 9 (9) . Extrapolating from these models, it is probable that the V-274 or W-275 and the V-279 or I-280 within E1 (272-285) respectively represent the first and second hydrophobic anchor residues for binding to HLA-DR. The third, or more allele-specific, anchor residue is likely to be the S-282 or Q-283. An earlier study (11) revealed that T cell clone AT177C5 was optimally cytotoxic when the peptide E1 (272-285) was used to sensitize target cells, while removing or adding residues at either end of the sequence resulted in lower rates of target cell killing. These observations suggest that residues extraneous to the core T cell epitope may influence peptide-HLA interaction and subsequent recognition by the AT177C5 clone. This may also account for the different levels of cytotoxicity observed in the present study (Table 3 ) using E 1(273-284) and E 1(272-282).
In this study we used both EBV-BLs (Table 1 ) and DR|3 chain transfectants of BLS-1 and MAT cell lines (Table 2) to characterize the HLA restrictive elements of the E1 (273-284) peptide-specific CTL clone, AT177C5. We found that HCLs with DR4 subtypes B1*0403, B1*0406 and B1*0407 which have in common glutamic acid (E) at position 74 in their (J chains, could present both E1 (273-284) and E1 (272-282) peptides to this T cell clone. The significance of the position 74 substitution (E for A) was confirmed by the dramatic differences in cytotoxicity towards the E1 (273-284) peptidesensitized targets, between BLS-1 and MAT cell DR4Dw13p (DRB1*0403, position 74 = E) and DR4Dw14p (DRB1*0404, position 74 = A) transfectants.
Peptide-HLA binding studies revealed that biotinylated E1 (272-285) bound with varying degrees to both DR4 and
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DR5 BLS-1 transfectants (BLS-1.aDR4Dw13P, aDR4Dw14p, aDR4Dw4(3 and aDR5p), suggesting that the structural differences between these DR alleles did not impede peptide binding with these DR molecules. The ability of a peptide to bind multiple DR alleles might reflect the high degree of structural homology within the binding grooves of these DR alleles (34-36). As noted above, E1 (272-285) peptide appears to contain anchor residues which include in the DR5 and DR4Dw4 binding motifs recently proposed by Sette and Rothbard et al (33, 37, 38) In contrast, DR3-binding motifs [i.e. the motif with aspartic acid (D) at position 4 as the specific contact site] are distinct from those recognized by other major DRB1* chains (35, 36) . This is consistent with our observation that biotinylated E1 (272-285) bound to the DR4 and DR5 transfectants, (BLS-1.aDR4Dw4p, DR4Dw13p, DR4Dw14p, and DR5P) but not to BLS-1.aDR3P(DRB1*0301) (28) . Interestingly, the particular motif (with D at position 4) recognized only by DRB1*03 and DRB3*01 has been suggested recently to be related to a position 74 residue substitution, arginine (R), which is only found in these two DRp chains (2, 39) .
We found that B-E1 (272-285) bound to BLS-1.cxDR4Dw13p (DRB1*0403) and BLS-1.CXDR4DW14P(DRB1*0404) with similar affinity, suggesting that the polymorphism at position 74 (E to A) did not have a major effect on the binding of E1(272-285) to HLA-DR4 molecules. To further analyze how the amino acid substitution (E to A) at position 74 influenced T cell recognition of E1 (272-285), we devised a T cell effector-B cell target conjugate assay to test the ability of the AT177C5 TCR to engage with the peptide-DR complex on an antigenpresenting B cell. We found that AT177C5 T cells bound to E1(272-285)-pulsed BLS-1.ocDR4Dw13P (DRB1*0403) cells at a higher frequency than with peptide-pulsed BLS-1 .aDR4Dw14p (DRB1 *0404) cells and that the dose-response kinetics of conjugate formation paralleled that of cytotoxicity assays. This suggested that the binding affinities of the TCR and peptide-DR complex were affected by the different position 74 residues on these DR4 molecules. That charged amino acids (especially negatively charged residues within a helices of DRp chains) strongly influenced T cell recognition has been established (40) Due to its central location within the peptide-binding groove of HLA-DR, substitutions at position 74 of the DRp chain could be particularly influential (2, 41, 42) in this regard. Our findings suggest that although substitution of A for E at position 74 of the DR4p chain did not prevent binding of the peptide, E1 (272-285), the peptide may have assumed a different conformation with each of the position 74 DR4 variants. This, in turn, may have altered the contacts between the peptide-HLA complexes and the TCR of the CTL clone resulting in altered recognition. Alternatively, direct TCR contact sites on the DR molecule may be critically dependent on the physicochemical characteristics of the position 74 residue. Thus, our results are consistent with previous observations in mice and humans (41) (42) (43) concerning the influence of the position 74 (75 of I-Ep chain in mice) residue on the presentation of antigenic peptides to T cells. Moreover, as DRP chain polymorphisms at positions including 74 have been associated with predisposition to rheumatoid arthritis (44, 45) , we anticipate further studies of the association of DR4 position 74 variation with autoimmune disorders linked to RV including rubella vaccine-associated arthritis
